Why Is BAUSCH HEALTH COS IN (BHC) Stock Up Today?

BHC stock rose 4.24% to $6.64 on Thursday, driven by a product availability announcement and stronger-than-expected earnings results. The stock opened at $6.39 and climbed to a session high of $6.65 shortly after the market opened. The move comes as Bausch Health reported better-than-expected Q2 adjusted earnings and raised its full-year 2026 sales guidance.

What Happened

Bausch Health announced that Solta Medical’s Fraxel FTX® is now available to Australian healthcare practitioners starting September 1, 2026. This next-generation skin resurfacing technology is expected to expand the company’s presence in the aesthetic and dermatological markets. Separately, the company reported Q2 adjusted earnings of $1.26 per share, exceeding the $1.04 estimate. Sales for the quarter reached $2.852 billion, surpassing the $2.661 billion estimate. Based on these results, Bausch Health raised its FY2026 sales guidance to a range of $10.790 billion to $11.040 billion, above the $10.773 billion consensus estimate.

What The Data Shows

BHC has a market cap of $2.4 billion and remains unprofitable, with a trailing twelve-month (TTM) net margin of -10.1%. Despite this, the stock has shown strength in recent trading, with 7 fresh 52-week highs and 1 fresh 52-week low recorded on September 1. Intraday volume was 0.2 million shares, or 0.1 times the 3-month average. A recent insider transaction saw Aimee J. Lenar, President of US Pharma, sell shares on August 19, with no insider purchases reported in the last 90 days.

What To Watch

The company’s performance in the coming quarters will be critical, particularly as it continues to roll out new products like Fraxel FTX® and executes on its revised sales guidance. Investors should monitor quarterly earnings reports and product adoption rates in key markets.